ArticleJournal of clinical medicine2022

The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma.

Shou-Wu Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.